Dr. Nanus on Next Steps With Atezolizumab in Patients With mUC

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses unanswered questions that remain with atezolizumab (Tecentriq) regarding the treatment of patients with metastatic urothelial carcinoma (mUC).

One of the biggest remaining questions with atezolizumab is finding a biomarker to determine which patients are most likely to respond to the agent, Nanus explains. More than one biomarker will likely be needed, he adds.

Additionally, the duration of treatment with atezolizumab has not yet been determined.